Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | NAMPT | P43490 | 6/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16639757 | 0.91 | RAB9A (0.61) | SENP1NAMPTMAPTHPGDSMN1; SMN2 | |
| SCHEMBL16639764 | 0.76 | KDM4E (0.66) | KDM4ENAMPTMAPTHPGDSMN1; SMN2 | |
| SCHEMBL22166400 | 0.73 | KDM4E (0.55) | KDM4ENAMPTSMN1; SMN2LMNA | |
| SCHEMBL31562927 | 0.71 | NAMPT (0.75) | NAMPT | |
| SCHEMBL15276799 | 0.71 | LMNA (0.70) | SMN1; SMN2LMNARAB9APOLB | |
| SCHEMBL3455567 | 0.71 | ALDH1A1 (0.71) | SENP1KDM4EMAPTHPGDSMN1; SMN2 | |
| SCHEMBL164751 | 0.71 | NAMPT (1.00) | NAMPTMAPTKMT2AMEN1 | |
| SCHEMBL31562898 | 0.70 | NAMPT (0.64) | NAMPTHPGDLMNAKMT2AMEN1 | |
| SCHEMBL12726993 | 0.70 | BCKDK (0.68) | SENP1KDM4EMAPTHPGDSMN1; SMN2 | |
| SCHEMBL16644219 | 0.70 | POLB (0.55) | NAMPTMAPTSMN1; SMN2LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10696692-B2 | Amido-benzyl sulfone and sulfoxide derivates | Valo Health, LLC | 2020-06-30 | — | — | US | disclosed |
| US-20150104384-A1 | AMIDO-BENZYL SULFONE AND SULFOXIDE DERIVATIVES | VALO HEALTH, INC. | 2015-04-16 | — | — | US | disclosed |
| US-20150104384-A1 | AMIDO-BENZYL SULFONE AND SULFOXIDE DERIVATIVES | VALO HEALTH, INC. | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696692-B2 | Amido-benzyl sulfone and sulfoxide derivates | STS, SQOR, SULT1E1 | SENP1 830/4885KDM4E 594/4885NAMPT 459/4885 |
| US-20150104384-A1 | AMIDO-BENZYL SULFONE AND SULFOXIDE DERIVATIVES | STS, SULT1E1, CBS | SENP1 1081/4885KDM4E 661/4885NAMPT 759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.